期刊文献+

奥沙利铂加卡培他滨治疗老年晚期胃肠道癌35例

原文传递
导出
摘要 目的观察奥沙利铂加卡培他滨(商品名:希罗达)治疗老年晚期胃肠道癌的疗效及安全性。方法对收治的老年晚期胃肠道癌采用奥沙利铂135mg/m^2,静脉滴注3h,第1天;卡培他滨1000mg/m^22次/d,口服,第1天至第14天,每3周重复。结果完全缓解2例,部分缓解14例,稳定8例,进展11例,总有效率45.7%(16/35),其中胃癌有效率42.8%(6/14),大肠癌有效率52.3%(11/21),毒副作用主要为输液肢体麻木,Ⅰ-Ⅱ度骨髓抑制及胃肠反应,Ⅲ度以上少见,少数患者有Ⅰ度手足综合征。结论奥沙利铂加卡培他滨方案治疗老年晚期胃肠道癌疗效确切,毒副作用小,耐受性好,患者依从度高,可多疗程使用,有利于提高疗效,可作为治疗老年晚期胃肠道癌的首选方案。
出处 《肿瘤研究与临床》 CAS 2009年第6期419-420,共2页 Cancer Research and Clinic
  • 相关文献

参考文献3

二级参考文献22

  • 1开普拓临床协作组.开普拓治疗晚期大肠癌临床研究[J].中华肿瘤杂志,2002,24(2):188-190.
  • 2Koizumi W, Saigenji K, Nakamaru N,et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor [J]. Oncology,1999;56(3) :215-222.
  • 3Takiguchi N, Nakajima N, Saitoh N, et al. A phase Ⅲ randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer[J]. Int J Oncol, 2000 , 6 (5): 1021-1027.
  • 4Miyadera K, Sumizawa T, Haraguchi M, et al . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase[J]. Cancer Res,1995,55(8): 1687-1690.
  • 5Maeda K, Chung YS, Ogawa Y, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma[J]. Br J Cancer, 1996,73 (8): 884-888.
  • 6Mata JF, Garcia Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 [Prime] - deoxy- 5- fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug[J ]. Mol Pharmacol,2001,59(6): 1542.
  • 7Miwa M, UraM, NishidaM, etal. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer, 1998,34(8) :1274-1281.
  • 8Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine[J]. Clin Pharmacokinet,2001,40(2) :85-104.
  • 9Blum JL, Jones SE, Buxdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,17 ( 2): 485 -493.
  • 10O'shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years[J]. Proc Am Soc Clin Oncol, 1998,17:398-406.

共引文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部